glp 1 select trial GLP-1 medications are not just for weight loss — they are the most important drug class of our lifetime. 🫀 A 2025 meta-analysis of 99,599 patients confirmed: ✓ 20% reduction in major GLP-1 Agonists For Obesity In

56.7% achieved 20% loss vs 3.1% placebo

[DOI] [PubMed] [Google Scholar] 36.Rayner CK, Watson LE, Phillips LK, et al

Your body is trying to conserve energy and find a new balance

The combination of GLP-1 receptor agonists and DPP-4 inhibitors is not recommended, not due to safety issues, but since a clinically significant additional benefit is not expected (see below) (7072)

Specifically, mutagenesis of ECD, ECL1 and ECL3 individually increased the basal activity of GCGR, which could result from the interruption of intramolecular interactions between the ECD and ECL1/3 that otherwise stabilize the receptor in an inactive state